Arquivos: Materiais Educativos

COVID-19 - Discharge - Clinical Overview SynopsesClinicalKey Clinical Overviews provide additional specific guidance for:Coronavirus: novel coronavirus (COVID-19) infection GuidanceCoronavirus (COVID-19), Clinical Overview Synopsis ~KEY POINTS COVID-19 (coronavirus disease 2019) is respiratory tract infection due to a novel coronavirus, SARSCoV-2 (initially called 2019-nCoV);

Clinical Description - ARDSCare of the hospitalized child experiencing new onset of respiratory failure within 7 days of the initial insult, including bilateral infiltrates, an acute deterioration in oxygenation from baseline and refractory hypoxemia that cannot be explained by cardiac

Chloroquine monograph - Indications/Dosageexpand all | collapse all Labeled amebiasis malaria malaria prophylaxis Off-Label, Recommended coronavirus disease 2019 (COVID-19) † discoid lupus erythematosus † severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection † Per the manufacturer, this drug has been shown to be active against most strains of the

Clinical Description - Mechanical ventilation invasiveCare of the hospitalized child experiencing the need for controlled or assisted breathing through an artificial airway. Key Information Cuff must be deflated (if present) prior to using a speaking valve or capping a tracheostomy tube. Tubes

Chloroquine monograph - Indications/Dosageexpand all | collapse all Labeled malaria malaria prophylaxis rheumatoid arthritis systemic lupus erythematosus (SLE) Off-Label, Recommended coronavirus disease 2019 (COVID-19) † lupus nephritis † polymorphous light eruption † severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection † Per the manufacturer, this drug has been shown to be

Recent publications have brought attention to the possible benefit of chloroquine, a broadly used antimalarial drug, in the treatment of patients infected by the novel emerged coronavirus (SARS-CoV-2) (Colson et al., 2020; Gao et al., 2020). The scientific community should